Specializes in developing innovative therapies for urological and oncological diseases.
UroGen Pharma Ltd., a pioneering biotechnology firm, focuses on advancing innovative solutions for specialty cancers and urothelial diseases. At the forefront of its offerings is RTGel, a biocompatible polymeric hydrogel with reverse thermal gelation properties designed to enhance the therapeutic efficacy of existing drugs. The company's notable product, Jelmyto, utilizes RTGel in a pyelocalyceal solution, offering a novel treatment approach. The cornerstone of UroGen Pharma's pipeline is UGN-102, currently in Phase III clinical trials. This candidate targets various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, the company is actively developing UGN-301, aimed at addressing high-grade non-muscle invasive bladder cancer, underscoring its commitment to meeting critical medical needs in urology. In fostering its growth and innovation, UroGen Pharma has established strategic partnerships and collaborations. These include a license agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of pharmaceutical products combining RTGel with clostridial toxins. Moreover, the company collaborates with Agenus Inc. to advance intravesical delivery treatments for urinary tract cancers. Additionally, a strategic research collaboration with MD Anderson Cancer Center aims to propel investigational treatments for high-grade bladder cancer. Founded in 2004 and headquartered in Princeton, New Jersey, UroGen Pharma Ltd. continues to drive forward with a robust pipeline and strategic partnerships, poised to make significant advancements in the treatment landscape for urological cancers and diseases.